IGC-501

**IGC-501** is an investigational fixed-dose cannabinoid-based anticonvulsant formulation developed by IGC Pharma that combines **cannabidiol** with **phenobarbital**. It is covered by patents describing use in seizure disorders and epilepsy in humans and animals; the development rationale is to combine cannabidiol-mediated cannabinoid-system activity with phenobarbital-mediated enhancement of inhibitory GABAergic neurotransmission. IGC has reported animal data in dogs indicating that the combination reduced seizure frequency more than either component alone. ([investor.igcpharma.com](https://investor.igcpharma.com/wp-content/uploads/2023/07/IGC-Pharma-Receives-Notice-of-Allowance-for-Patent-on-Seizures-Jun-623.pdf))

Other names

cannabidiol + phenobarbital